throbber
Jo Isurnol
`lecllnecstuJsrld
`secueps
`
`116I AUYONVf
`r ltsgl InN 99 Shrn'IoA
`
`'parJrluur
`u?t uorsn]u
`ar{l l€ql
`'ro^a
`IUJrlnaCeurJ
`
`Iural pi
`'slalqel se qens
`puB'spl
`uec urelsds
`.{pee1c sr 1r;r
`pue 'u8tsap'ur
`
`.{€ur
`
`puu a{olruJ
`luq? snlErl
`'sraddorpi
`p1no,r Suruear
`Uaqr[ U
`
`flTCIJAV lAgIAgA
`
`sllBs IBcl+nacBurrBqd
`
`PUa '* tr.flTH0rg 'C flT,tT '+* g0ugg 'IAtr NgHdtrJS
`' US0OH)INOIAI 'C CTVNO0
`
`-ocrsdqd'dceur.reqd lelaua8-s1ps leJr?naJEurr€qd O sesBJqd,{ay
`-rxo1 'serl.radord l€Jl?.nateurreqd
`'dlqrqele.ruorq 'serpado.rd lEJlrrraqc
`-ocrsdqd'dceurreqd lerauaS-lecrlnaceru.reqd'slleS Er mat.tar'd8o1or
`-rxo1'sarlradord lecrlnecerureqd'd1r1rqe1e,reotq'sarlrado.rd Pcluaqc
`'f,1qrqn1os'uorlnlossrp sallredord lecrruaqcocrsdq4 o rrrarla.r'd8o1or
`tr .&rarlal 'slles lecrlnoteurJeqd;o setlrado.rd olldaloue8ro pue 'f1qtqe1s
`-reqd pue uolleralle uorldrosqe'slreJJa uoll€lnur.ro;-dltltqelte.teotg
`-eur.reqd-,{SoloJlxo; E ,r\erlal'slles leJrlnac€rureqd 3o scIlaul{osutll
`.{el^ar'sJ.lBs IEcIlneJ
`
`S'LNSTNOC
`
`oql JO 'dlucrrrdura uasoqc ualJo arB slua8e Sunuro;-1pg
`,tq palealas sr ruJoJ parra;ard aq?'pazrsaqluds slps dueur
`:srwq leJrlcerd e uo dpreurrrd slslruaqc pctlnaceurreqd
`luacrad pue 'uor1ezr1p1s,frc 3o asea 'sleualeru rr\eJ Jo lsoe
`-dq id1r1qe1s opnlcur suol?€raplsuoc cISBq .raq16 'p1ad
`'8nrp rynq Sutlpsar aql Jo dlqrqe.trog pue 'dlrcrdocso.r8
`eq1 3u11e1pa.rd 3o deltt aIqBIIar ou sI aratll 'd1a1eun1.ro;un
`oq? Jo Jor^Br{eq aql uo sarcads lIBs rBIncI1.rBd e;o acuangut
`yo slps dueur .ral;e uala'aloruJaq?rnd'punoduroc
`lua.red
`luarcrlla ou 'paredard uaaq a,req lua8e JISBq arues aql
`l1es aq? Jo uollcalas alslIIIcBJ o? lslxa sanbruqcal Suruaa'rcs
`-nlos (crlaur4oceur.reqd paJISap aql llqqxa o1 ,t1a>1q lsour
`'sago.rd uol?BlnruroJ pue'd1qtq
`-ap uaaq'.ra.taltoq'a,rEq siapour 8ur>1ew-uotslcap aruos
`'aldurexa Jod 'ocueurro;rad 1ps lcrpard dlaq o1 padola.t
`lap,,'senbruqcal o^ ? paqlrcsap (1) outddy pue 3utp1p16
`pue .3'sISdIBue uralqord l€I?ualod,, pue ..sls^leua uoISIc
`-E^rrap alqu?ms lsour aq? Jo uol?3alas ar{l o? uroql paqdde
`aI{J 'lalqBl e se luaurdola^ap roJ pIcB cIuEEro uB Jo a^I?
`-rsselod aql pu€ pIJB aaq aql alaa\ poJoplsuoc saAIlBAIrap
`paseq aJB sanbruqcq qlog's?lus runlJlec pue'urntpos'utn
`asar$ Jo satlradord pcrSolorq pue'pcrs.(qd'lecnuaqc aql uo
`-ap JoJ enuo^B Sursrurord B JaJJO puB SaAI?BAIrap cgtcads
`'sruroJ 1ps purrldo 8utdo1a,r
`aq1 lnoq8no.rqi pas.radsrp dlaprm sr sll€s uo uotleurio;u1
`aql sossaJppe l{clq.t\ Jo qcnu 'arn1ura1r1 petlnacerureqd
`a^r?cB aql Jo as?alar ar{l Suolord ol uollBturoJ ?lES Jo asn
`Snrp alqe.rrsopun snoIJBA SuIlsuIurIIa dqaraql'luauoduroc
`^\al^ar
`?sEI aql Jo arnlBralq s^a^rns
`slI{J '(9-z) salFadord
`sarFadoJd aql uaa^qaq suoslJ€druoc Surzrseqdrua 'sread 96
`oslB papnlcul 'punoduoc oruEs ar{lJo surroJ lIBs ?uaraJJlp Jo
`asodJnd rno 'sruroJ l[ES lnJasn flet1ua1od;o UoISSnJSIp B sI
`lualaJJrp dueur aq1 Jo ^\aIAJaAo
`u8 ?uasald ol :ploJo^\l sI
`pue uasoqc aq uBJ salBplpu€J Snrp alau qclqd'uro4 slles
`
`| / ll6t ttonuop'I oN'99'IoA
`
`68Lgtz
`
`OI
`OI
`II
`II
`'I8I
`1I
`VT
`II
`9I
`9I
`9I
`9I
`9I
`
`" " s??rs ptas1 K.1nt1ua1o4
`''' "' salpnls ytnutatl'tu)ts,(t1,1
`" " elBU uorlnlossl(
`
`,{1lllqulS
`
`' Kltltqnymonoq
`"'i"
`' s?taJJg uollulnlurod
`: *#i{fh|ii:i;$'
`
`:: ::::: ::. :: :::: ::::: :"j11i*i{:l'iffi:il3
`::::::::::
`:
`:
`
`lcaJJg PcrSoloceurreq6
`" "'
`'" " srsllurg
`. . . . . . . . . . . : . . . . . . . . . . . . . . . . . . .:y?!;::??::":?JJ;;iiJ#
`' ' uoJ llES Jo '{lIrIxoJ
`urro.d ?TBS lo dltctxo;
`"' suolsnpu1c
`sDuala|aA
`""
`-rBqJ crruouoca puE'pcrs.{qd'prr8olotq'pcturaqc eq;
`'pue palepdluBru aq uec slua8e IBuIcIpau Jo sJIlsIralJB
`'urroJ ?lBS B ol uolsJa,ruoc dq pezturtldo ua1;o 'acuaq
`dral e aq uBJ 'ralanoq '11es aler.rdoJdde aql Sursooq3
`o1 saq.rado.rd anbrun slredurr 1IBS t{cea acuts '>1se1 lFllJJlp
`'punoduroc luared aql
`
`'i""'
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 1
`
`

`
`Table I-FDA-Approved Commercially Marketed Salts
`
`Anion
`
`Acetate
`Benzenesulfonate
`Benzoate
`Bicarbonate
`Bitartrate
`Bromide
`Calcium edetate
`Camsylateb
`Carbonate
`Chloride
`Citrate
`Dihydrochloride
`Edetate
`Edisvlate'
`Estoiated
`Esylate''
`Fumarate
`Gluceptate/
`Gluconate
`Glutamate
`Glycollylarsanilates
`Hexvlresorcinate
`Hydrabamineh
`Hydrobromide
`Hydrochloride
`Hydroxynaphthoate
`
`Cation
`
`Percento
`
`"Anion
`
`Percento
`
`7.26
`0.25
`0.51
`0.13
`0.63
`4.68
`o.25
`0.25
`0.38
`4.t7
`3.03
`0.51
`0.25
`0.38
`0.13
`0.13
`0.25
`0.18
`0.51
`0.25
`0.13
`0.13
`0.25
`1.90
`42.98
`0.25
`
`Iodide
`ISethionatet
`Lactate
`Lactobionate
`MaIate
`Maleate
`Mandelate
`Mesylate
`Methylbromide
`Methylnitrate
`Methylsulfate
`Mucate
`Napsylate
`Nitrate
`Pamoate (Embonate)
`Pantothenate
`Phosphate/diphosphate
`Polygalacturonate
`Salicylate
`Stearate
`Subacetate
`Succinate
`Sulfate
`Tannate
`Tartrate
`Teoclatej
`Triethiodide
`
`2.O2
`0.88
`0.76
`0.13
`0.13
`3.03
`0.38
`2.02
`0.76
`0.38
`0.88
`0.13
`0.25
`0.64
`1.01
`0.25
`3.16
`0.13
`0.88
`0.25
`0.38
`0.38
`7.46
`0.88
`3.54
`0.13
`0.13
`
`Percenta
`
`Cation
`
`Percento
`
`Metallic:
`Organic:
`Aluminum
`BenzathineA
`0.66
`0.66
`Calcium
`10.49
`Chloroprocaine
`0.33
`Lithium
`0.33
`Choline
`1..64
`Diethanolamine
`Magnesium
`1.31
`0.98
`Ethvlenediamine
`Potassium
`10.82
`0.66
`Sodium
`Mejluminel
`6t.97
`2.29
`Zinc
`2.95
`Procaine
`0.66
`n Percent is based on total number ofanionic or cationic salts in use through 19?4. 6 Camphorsulfonate. " 1,2-Ethanedisulfonate. d Lauryl sulfate
`t 2-Hydroxyethanesulfonate.
`,' Ethanesulfonate. / Glucohepronuls. sp-Glycollamidophenylarsonate. h N,N'-Di(dehydroabietyl)ethylenediamine.
`r 8-Chlorotheophyllinate. t ,rtr,N'-Dibenzylethylenediamine. I N-Methylglucamine.
`
`to assemble data that will provide, for the student and
`practitioner alike, a rational basis for selecting a suitable
`salt form.
`
`POTENTIALLY USEFUL SALTS
`Salt formation is an acid-base reaction involving either
`a proton-transfer or neutralization reaction and is there-
`fore controlled by factors influencing such reactions.
`Theoretically, every compound that exhibits acid or base
`characteristics can participate in salt formation. Particu-
`larly important is the relative strength of the acid or
`base-the acidity and basicity constants of the chemical
`species involved. These factors determine whether or not
`formation occurs and are a measure of the stability of the
`resulting salt.
`The number of salt forms available to a chemist is large;
`surveys of patent literature show numerous new salts being
`synthesized annually. Various salts of the same compound
`often behave quite differently because of the physical,
`chemical, and thermodynamic properties they impart to
`the parent compound. For example, a salt's hydrophobicity
`and high crystal lattice energy can affect dissolution rate
`and, hence, bioavailability. Ideally, it would be desirable
`if one could predict how a pharmaceutical agent's prop-
`erties would be affected by salt formation.
`Tables I and II list all salts that were commercially
`marketed through 1974. The list was compiled from all
`agents listed in "Martindale The Extra Pharmacopoeia,"
`
`2 I Journal of Pharmoceutical Sciences
`
`26th ed. (7). Table I categorizes all salt forms approved by
`the Food and Drug Administration (FDA), while Table II
`lists those not approved by the FDA but in use in other
`countries. (Only salts of organic compounds are considered
`because most drugs are organic substances.) The relative
`fre.quency with which each salt type has been used is cal-
`culated as a percentage, based on the total number of an-
`ionic or cationic salts in use through 1974. Because of
`simple availability and physiological reasons, the mono-
`protic hydrochlorides have been by far the most frequent
`choice of the available anionic salt-forming radicals, out-
`numbering the sulfates nearly six to one. For similar rea-
`sons, sodium has been the most predominant cation.
`Knowledge that one salt form imparts greater water
`solubility, is less toxic, or slows dissolution rate would
`greatly benefit chemists and formulators. In some cases,
`such generalizations can be made. Miller and Heller (8)
`discussed some properties associated with specific classes
`of salt forms. They stated that, in general, salt combina-
`tions with monocarboxylic acids are insoluble in water and
`lend themselves to repository preparations, while those of
`dicarboxylic acids confer water solubility if one carboxylic
`group is left free. Pamoic acid, an aromatic dicarboxylic
`acid, is an exception since it is used as a means of obtaining
`prolonged action by forming slightly soluble salts with
`certain basic drugs. Saias ef ol. (9) reviewed the use of this
`salt form in preparing sustained-release preparations.
`More recently, latentiation of dihydrostreptomycin (10)
`
`Table II-
`Salts
`
`Adipate
`Alginate
`Aminosalicl
`Anhydrome
`Arecoline
`Aspartate
`Bisulfate
`Butylbromir
`Camphoratr
`Digluconate
`Dihydrobror
`Disuccinate
`Glvcerophos
`Hemisulfate
`Hydrofluori
`Hydroiodidr
`Methyieneb
`Napadisylat
`Oxalate
`Pectinate
`Persulfate
`Phenyiethyl
`Picrate
`Propionate
`Thiocyanate
`Tosylate
`Undecanoat
`
`Cation
`
`Organic:
`Benetharn
`Clemizole
`Diethylan
`Piperazinr
`Trometha
`Metallic:
`Barium
`Bismuth
`
`" Percent
`through 1974
`a 1-p-Chlorc
`droxymethyl
`
`using pam
`action prel
`are disperl
`Alginic
`pharmacer
`and showr
`tions. A st
`that of pil
`dried to a r
`preparatic
`While liqu
`ride salts I
`that solid 1
`more effec
`nificantly
`Solid dose
`because it
`which hok
`commonly
`immediatr
`M6lek e
`action thrr
`tribution c
`by merely
`molecules
`l5rmphatic
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 2
`
`

`
`Table l-tr'DA-Approved Commercially Marketed Salts
`Percento
`
`Anion
`
`Percent"
`
`Table II-l
`Salts
`
`Acetate
`Benzenesulfonate
`Benzoate
`Bicarbonate
`Bitartrate
`Bromide
`Calcium edetate
`Camsylateb
`Carbonate
`Chloride
`Citrate
`Dihvdrochloride
`Edetate
`Edisvlate'
`Estoiated
`Esylate"
`Fumarate
`Gluceptate/
`Gluconate
`Glutamate
`Glycollylarsanilater
`Hexvlresorcinate
`Hydrabamineh
`Hydrobromide
`Hydrochloride
`Hydroxynaphthoate
`
`Cation
`
`1.26
`0.25
`0.51
`0.13
`0.63
`4.68
`0.25
`0.25
`0.38
`4.77
`3.03
`0.51
`0.25
`0.38
`0.13
`0.13
`0.25
`0.18
`0.51
`0.25
`0.13
`0.13
`0.25
`1.90
`42.98
`0.25
`
`,Anion
`
`Iodide
`Isethionatet
`Lactate
`Lactobionate
`Malate
`Maleate
`Mandelate
`Mesvlate
`Metirylbromide
`Methylnitrate
`Methylsulfate
`Mucate
`Napsylate
`Nitrate
`Pamoate (Embonate)
`Pantothenate
`Phosphate/diphosphate
`Polygalacturonate
`Salicylate
`Stearate
`Subacetate
`Succinate
`Sulfate
`Tannate
`Tartrate
`Teoclatej
`Triethiodide
`
`2.02
`0.88
`0.76
`0.13
`0.13
`3.03
`0.38
`2.02
`0.76
`0.38
`0.88
`0.13
`0.25
`0.64
`1.01
`0.25
`3.16
`0.13
`0.88
`0.25
`0.38
`0.38
`7.46
`0.88
`3.54
`0.13
`0.13
`
`Adipate
`Alginate
`Aminosalicyle
`Anhydrometl
`Arecoline
`Aspartate
`Bisulfate
`Butylbromidt
`Camphorate
`Digluconate
`Dihydrobrom
`Disuccinate
`Glycerophosp
`Hemisulfate
`Hydrofluorid
`Hydroiodide
`Methylenebis
`Napadisylate
`Oxalate
`Pectinate
`Persulfate
`Phenylethylb
`Picrate
`Propionate
`Thiocyanate
`Tosylate
`Undecanoate
`
`Cation
`
`Organic:
`Benethami
`Clemizoled
`Diethylami
`Piperazine
`Tromethar
`Metallic:
`Barium
`Bismuth
`
`" Percent ii
`through 1974.
`d 1-p-Chloroi
`droxymethyll
`
`using pam(
`action pret
`are dispers
`Alginic z
`pharmaceu
`and shown
`tions. A str
`that of pik
`dried to a s
`preparatio
`While liqu
`ride salts 1
`that solid 1
`more effec
`nificantly
`Solid dose
`because it
`which holc
`commonly
`immediate
`M6lek e
`action thrr
`tribution c
`by merely
`molecules
`lymphatic
`
`Percent"
`
`Cation
`
`Percent"
`
`Metallic:
`Organic:
`0.66
`Aluminum
`0.66
`Benzathineh
`10.49
`Calcium
`0.33
`Chkrroprocaine
`1.64
`Lithium
`0.33
`Choline
`1.31
`Magnesium
`0.98
`Diethanolamine
`10.82
`Potassium
`0.66
`Ethvlenediamine
`61.97
`Sodium
`2.29
`Megluminel
`2.95
`Zinc
`0.66
`Procaine
`n percent is based on total number ofanionic or cationic salts in use through_1974. bCamphorsulfonate. " 1,2-Ethanedisulfo-nate. d.Lauryl.sulfate.
`";;-dt;"li;ia"pt'""r,t'.""rte. I' AiN' Di(dehydroabietyl)ethylenediamine.
`t 2-Hydroxvethanesulfonate.
`. ntiri"".rirJ""t"-] di;;;1;;;;;;;
`I N-Methylglucamine.
`, g-chlorotheophyltinal,e. h N,N'-Dibenzylethylenediamine.
`
`to assemble data that will provide, for the student and
`practitioner alike, a rational basis for selecting a suitable
`salt form.
`
`POTENTIALLY USEFUL SALTS
`Salt formation is an acid-base reaction involving either
`a proton-transfer or neutralization reaction and is there-
`fore controlled by factors influencing such reactions.
`Theoretically, every compound that exhibits acid or base
`characteristics can participate in salt formation. Particu-
`larly important is the relative strength of the acid or
`base-the acidity and basicity constants of the chemical
`species involved. These factors determine whether or not
`formation occurs and are a measure of the stability of the
`resulting salt.
`The number of salt forms available to a chemist is large;
`surveys of patent literature show numerous new salts being
`synthesized annually. Various salts of the szrme compound
`often behave quite differently because of the physical,
`chemical, and thermodynamic properties they impart to
`the parent compound. For example, a salt's hydrophobicity
`and high crystal lattice energy can affect dissolution rate
`and, hence, bioavailability. Ideally, it would be desirable
`if one could predict how a pharmaceutical agent's prop-
`erties would be affected by salt formation.
`Tables I and II list all salts that were commercially
`marketed through 1974. The list was compiled from all
`agents listed in "Martindale The Extra Pharmacopoeia,"
`
`2 / Journal of Pharrnaceuticol Sciences
`
`26th ed. (7). Table I categorizes all salt forms approved by
`the Food and Drug Administration (FDA), while Table II
`lists those not approved by the FDA but in use in other
`countries. (Only salts of organic compounds are considered
`because most drugs are organic substances.) The relative
`flequency with which each salt type has been used is cal-
`culated as a percentage, based on the total number of an-
`ionic or cationic salts in use through 1974. Because of
`simple availability and physiological reasons, the mono-
`protic hydrochlorides have been by far the most frequent
`choice of the available anionic salt-forming radicals, out-
`numbering the sulfates nearly six to one. For similar rea-
`sons, sodium has been the most predominant cation.
`Knowledge that one salt form imparts greater water
`solubility, is less toxic, or slows dissolution rate would
`greatly benefit chemists and formulators. In some cases,
`such generalizations can be made. Miller and Heller (8)
`discussed some properties associated with specific classes
`of salt forms. They stated that, in general' salt combina-
`tions with monocarboxylic acids are insoluble in water and
`lend themselves to repository preparations, while those of
`dicarboxylic acids confer water solubility if one carboxylic
`group is left free. Pamoic acid, an aromatic dicarboxylic
`acid, is an exception since it is used as a means of obtaining
`prolonged action by forming slightly soluble salts with
`certain basic drugs. Saias et ol. (9) reviewed the use of this
`salt form in preparing sustained-release preparations.
`More recently, Iatentiation of dihydrostreptomycin (10)
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 3
`
`

`
`DIUAJJod
`
`poterlretr tr l(lelcreururo3 pero.rcldy-Vqg-uoN-Il olq"I
`stlss
`
`7,0'z
`880
`9r'0
`8r'0
`8r'0
`808
`880
`z0'7,
`9/'0
`88'0
`880
`8r'0
`gz'0
`19'0
`IO'I
`97,'0
`9r'8
`8I'0
`88'0
`9Z'0
`880
`88'0
`9r'L
`880
`t98
`8r'0
`8I'0
`
`olUA3JOd
`
`990
`67'0i
`19 I
`I8'I
`z8 0r
`t6'r9
`967,
`
`'a1e.;ps 1drne1
`'alBuoJInsauPq
`
`dq pa.torddu
`II alqBJ alrq
`raqlo w asn
`peJaprsuoc a,
`aArlBIor or{f
`-IBc sr pasn I
`-uB Jo roqwr
`Jo asnEcag'
`-ouou aql 's
`luanbaq 1so
`-1no'slucrpu
`-€aJ JBIrrUrS,
`'uorlBJ I
`Ja?B1r{ JalBaJ
`pFo^{ alBr r
`'sas?c atuos r
`(g) ra11eg pr
`sassBlc JrJrcs
`-BurqruoJ 1l€
`puB ralBll\ ur
`Jo asoql aIIt{1
`crldxoqrec ar
`aqdxoqrecrp
`8ururc1qo;o r
`qll^\ sllBs al
`srql lo Osn arl
`'suorlerudarr
`(91) urcdurol
`
`uoruY
`
`aludrpy
`a1eut31Y
`aleldctlesoututY
`a1e.r1rcauai.(qlaurorpdquy
`auIToceIY
`alelredsY
`eJalTnsrS
`aPtutolqldlng
`aleroqduu3
`aleuotnlSl0
`apturorqorplqlq
`alsultcnsl(
`al€qdsoqdoratdlN
`al€JInsIrxaH
`apuonUorp,{H
`aPtPoto.tPlg
`1 a1u1.{.I1es.;srqaua[{q}atr tr
`n aleldstpedeS
`a1€lex0
`al€ullrad
`alElTnsrad
`alernlrqreqldqlalduaq4
`alBJJrd
`aluuotdor4
`a1eue.{cotq;
`a1e1.{so;
`aleouuc0pull
`
`uoIlBc
`
`o?uacJod
`
`gr'0
`8r'0
`9Z'0
`8r'0
`8r'0
`9Z'0
`9Z'0
`8r'0
`8r'0
`8r'0
`8T'0
`8I'0
`88'0
`8I'0
`8I'0
`9Z'0
`8I'0
`€r'0
`9A'0
`8r'0
`8T'0
`8r'0
`8I'0
`8r'0
`8r'0
`8I'0
`8I'0
`
`D?uacJod
`
`:Jru?5J0
`.aurIueqlauag
`palozrIualS
`aururel.{q1erq
`aurzeradr6
`,aururBqJaluorJ
`:OIIIBletr{
`runrJB[l
`qlnruslg
`truolJEc pu€ cIuoIuB Jo Jaqunu ]€lo? uo pesEq sI luaJJod D
`asn ur s?.I€s
`'auiurelfqleueqdl.{zuag-p .'aleuoJlnsrpauapqlqde5l-g'1 e'tl6I q8nor{l
`-^q)srrJ,'aroz'prulzuaql.{q1aru1d-,1-",p;il:.11"-?il;H."{n:ffi51,iT:
`
`88'0
`88'0
`88'0
`86'0
`88'0
`
`e8'0
`86'0
`
`1
`
`-padelap B Jo uolleruroJ aq? ul pallnsar plce crourud Sursn
`qIBs aleorued Sutsn salpn?s snorarunN 'uotle.redard uotlcu
`'(gI-iI) arn?uralrl aql ?noq8no.rql pas;adstp ere
`3ur1cu-3uo1 e.redard ol pasn uaaq s€q osp pIcB ctutFly
`(91 ) peredard sem aleu#p urcduolda4s'spcllnaceurreqd
`-e.rederd as"elar-peurBlsns ur a^lltaJJa aq ol u^loqs puE
`sr 1ps aleur8p 8ut1ce-8uol E Jo aldruexa 3ut1tr1s V 'su0l1
`rolBrt\ allrals ut pasradsrp uaqM 'eu'rd.recoltd 1o ]e{1
`pu€
`aql ur InJesn punoJ s€^\ punoduoc sq1 '193_plos B o? palrp
`j9 suiroy a8esop cturpqlqdo 8ur1ce-3uo_1 go uorlereda.rd
`-olqcorpdq pue a1eur31e aql Jo suoll€redard ptnbq a1tq16
`paaoqs salpnls 'd1t.tl1ce JIloIu rBlIluISr ssassod slps apIJ
`ezrs pdnd palclJlsuoc sa>1eg a1eur31e aurd.recoltd pqos leql
`-8rs stsorur;o uollernp aql pas€arcut pue dla,rtlaaJJa arolu
`'suorlereda.rd plnbq aql qllrla pareduroc uaq,u d11uecg1u
`'alqegenu .{1uuo;tun aloru aq deur aurdrecoltd esop ptlog
`xrr?Eur 1aB aql q8norrll .{1lro1s arour sosnJJlp }l asn€caq
`aql Jo sdorp '1ser1uoa uI 'aAJosaJ ut Snrp aql sploq qclq^\
`asop aql asBaIaJ turo; a8esop uollnlos padoldura.{luoruuror
`'pmg 1e^Ilcunluoc aql o1 ,t1e1etp0urut
`Sur8uolo.rd;o derrr anbrun B pasllap (gf) 'to ?a {algl tr
`l.ip .qt l€ql pa^\ot{s daql luolleuuoJ ll€s q8nolq1 uot}cu
`porall€ dlparyeur aq plnor scllolql?ue IBraAas Jo uollnqlr?
`-olceu acws 'slles relncaloruorceur Surredo;d dlaraur dq
`aql roJ dlrur;;e uB o^Bq salctlred leplolloc pue solncalou
`pue'urc,{tuotl'utcdutoau'utcduroldarls'uralsds ctleqdu'ri1
`
`'
`
`lqSraru relncalotu qFFI q?yrl paulqruoc ara,tr uraf.rq1o1de.r1s
`-soqd ro JIuoJIns'sprce crldrcedlod se qcns spunoduroc
`;saarle,rtrap cruo.rndlod pue'sapr.reqccesdlod paluldroqd
`pacnpo.rd spunodruoc asaql Jo uoll€rlsplurpe
`l€ra?ual€d
`ailqrrr 'sporrad 3uo1 JoJ crlolqlluB eql Jo sla^al poolq /t\ol
`uraduolda.rls 'uostleduloc uI) 'q8tq a.ren qa.lal qdulrtl
`srql ('s1ara1 qdurdl a\ol lnq sla^al poolq q8tq ane8 alBJIns
`o1 urodruoldarls eql pasn?J uollnqlJlslp uI uol?Broll€
`crleqdurdl acurs 'r{poq aq1 q8no.rql a8essed s1r 8uo1o.td
`'no1s altnb sI uoI?BIncJIJ
`ol punoJ uaaq s€q urJoJ 1l3s B Jo acloqc alerrdoldde aq;,
`punoduroc due 1eq1 pazII€uoIlEJ aq u€c 11 'd1tctxo1 aJnpaJ
`{urrp pu€ pooJ Jo ursqoqBlau l€rurou aql q}p\ pal€Icoss€
`Eursooqc 3o qceordde aqJ 'clxoluou dletluassa aq lsnru
`pazrloqulau Jo palarcxa .{lpear ere leql slBcIpBJ crueS.ro
`^\au
`lcolas 01 t{clqa uroq secuulsqns Jo ss€lJ
`e dn pauado
`aseq 8uor1s ar{l Jo sIIBS uIBlJac 'aldruexa Jod 'ruJoJ llES s
`Jraql u€q}
`tIXo? ssel dlqe.reprsuoc aq o1 ualo.td aA€q auqoqJ
`.;o sarlrado.rd pue uorle.redard aq;, 'punoduroc luared
`oJa^\ salrleAr.rap aurlldqdoaql yo salras € Jo slles auqoqc
`aleuqldqdoaql auloqc ?pql u^\or{s sB^\ 1I ptre'(61) pagodar
`raqlo slr .ro aullldqdoaql ueq? OsoT ra?Bar8 e passessod
`ssal aq plno^\ lue8e syql lBrI? palelnlsod se.u ?I '(02) s?IB!
`slr,, asneJaq 'auq1fqdourruB uer{l lcerl IC oql ol 8ul?€?lrrl
`-uou .{1a1a1duoc lsorulB ue st 'aurloqc 'luanlllsuoc cIS€q
`crSolorsdqd aql q acuelJodurl 1enlce Jo ocuelsqns clxol
`auqoqc Jo uollEr€dald aql 01 pel asuopl^a stq1, ,,'durouoca
`sacueqrnlsrp IC aql ecnpar o1 1dura11e ue se (16) aleldcqes
`sarpnls F?ruITC'uoll€J?slultupe aleldcqes r{1l.^a palelcossB
`aouaprJul Ja,t\ol B pallcqa aleldctps aulloqc 1€ql poleJlpul
`Jo se^a pu€
`'sasop .raq8tq uI paleralol se^l 'ssorlslp IC Jo
`prce cq,{cqesldlace S3,&\ uBql luarled aql o? ?IJauaq raleerS
`'(ut.rtdse)
`sE pasn uaaq OAEI{ osl" suIluB}IA plc€ puB splcB oulluY
`-pBoc lBr{1 acuapr^a aql uo pasBg 's1ua8e Suturro;-1ps
`-lqllue aprsocdlSoulru€ qll^\ splce oultu€ Jo uoll€rlslultu
`Jo sIIBS plc€ oultue Jo salJas e 'd1tcrxo1 rlaql pacnpoJ scllo
`auo lnq il€ uI '(ZZ) pareda.rd s€^\ ulc^uroldarlsorpdqtp
`ar{l uBI{l Jo/r\ol oJa,!\ S?IBS asaql Jo saI}DIxo? alnce aq1 'asec
`aqJ, 'a?BJIns aql Jo dlrctxol
`ol€uoqlo?uBd pue al€qrocs€
`aql uet{l clxol ssal aq ol u.4aoqs pu€ pazlsaqluds a.ram osle
`"1nqro".n
`"tTrT#
`lsaq;rq ar{lp'r{
`eq1'paredard slps aq?Jo
`
`slps Suturroy JoJ pasn dluouuroc lsoul sulru€l$ ar{J
`cruaqlolued pu€ clqJocse are d1rctxo1. pacnpar Sutltqtqxa
`cruaq?oluBd asn 01 lsrrJ aql a;am (96) '?o ?a rallay 'splce
`sacduroldarls crsBq aql ,,3u1.{Jlxo?4p,, Jo suEaur B sE pIcB
`-uaqlolued aql Jo uollEr?slullup€
`leraluarBd'scllolqlluB
`-8rs e peq urc.{uroldarlso.rpdqrp pue urcdurolda.rls Jo sal€
`slec ur dlrcrxolo.rneu alnc€ Jo acuaplcul pacnpor dlluect;1u
`$Z-nZ) sarpnls luanbasqng 'so?eJlns aq? qlp\ par€druoc
`sB
`selBuer{lolrrEd aq1 1eq1 pa/roqs pue Surpury sF{l pa?roddns
`aleqrocsB aqJ/ 'CIxo? ssal aJE oslB utcdurot.l pue urcduroau 5o
`pcrSoloceur.reqd s1r pue pazlsaqlu^{s se.u utc.{uropuealo ;o
`-calur relncsnurerlul uodn '(66) pelrodar ara,l. satl.radord
`-soqd eql uBql uollBllJrl ssol paanpo.td 1t 's1er uI uoll
`'a1eqd
`JO a?{oqBlaur snoncouul uB (pIcB clozuaqopruelacy-d
`pasn uaaq suq (aulJn pue poolq I€rurou ut luasa.rd pIcB cIToJ
`qllnd s?lBs alq€ls sp1ar.{ 1r '.re1nct1red uI 's?lBS SutrBda.rd ut
`s?cnpoJd cldocsoJ8^q uJoJ ol pual aslAraq?o }€ql saulurB
`'(0g) sluauoduroc prcD leuolluoluoc qll^
`llES E Surururalap dq uasoqc sI ruroJ ll€s aql ua?Jo
`
`t / lL6I KtnnuoT'L oN'99 toA
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 4
`
`

`
`component that will pharmacologically antagonize an
`unfavorable property or properties exhibited by the basic
`agent. Salts of N-cyclohexylsulfamic acid are an example
`of the practical application of this approach. N-Cyclo-
`hexylsulfamic acid salts, better known as cyclamates, have
`a characteristic sweet, pleasing taste. Although presently
`under investigation by the FDA for potentially carcino-
`genic properties, salts incorporating this compoqnd can
`render unpleasant or bitter-tasting drugs acceptabie. For
`example, the cyclamates of dextromethorphan and
`chlorpheniramine exhibit greatly improved bitterness
`thresholds compared to commonly occurring salts (81.).
`Furthermore, their stability in aqueous solution was de-
`scribed as good when maintained at a pH not greater than
`4.
`
`N-Cyclohexylsulfamic acid salts of thiamine hydro-
`chloride and lincomycin also have been synthesized. Thi-
`amine N-cyclohexylsulfamate hydrochloride was reported
`to have a more pleasant taste than other thiamine salts
`while having an equal or greater stability (32). Lincomycin
`cyclamate, shown to possess an enhanced thermal stability
`over its hydrochloride, was prepared (33) to test the hy-
`pothesis that reduced lincomycin absorption in the pres-
`ence of small quantities of cyclamates was due to a simple
`metathetic reaction. However, this assumption was found
`not to be true. An extensive study of the preparation and
`characterization of cyclamic acid salts of several widely
`used classes of drugs including antihistamines, antibiotics,
`antitussives, myospasmol5rbics, and local anesthetics was
`reported (34,35).
`Various salts of penicillin and basic amine compounds
`have been formulated in an effort to produce a long-acting,
`nonallergenic form of penicillin. Since antihistamines
`appear to mitigate the symptomatology of penicillin re-
`actions in some patients, coadministration of the two has
`been advocated. The preparation of the benzhydralamine
`salt of penicillin was an attempt to produce a repository
`form of penicillin with antiallergic properties (36). Blood
`levels achieved with this salt were comparable to those of
`penicillin G potassium; however, its antiallergic properties
`were not evaluated. In fact, the investigators noted that
`antihistamines can actually cause sensitization at times
`and stated that "despite their occasionally favorable in-
`fluence on the symptoms of penicillin sensitivity, they
`contribute directly to the potential of drug sensitivity when
`co-administered with penicillin."
`Silver salts of sulfanilamide, penicillin, and other anti-
`biotics have been prepared and represent cases where the
`species (ions) are complementary. When aqueous solutions
`of the salts were applied topically to burned tissue, they
`yielded the combined benefits of the oligodlmamic action
`of silver and the advantages of the antibacterial agents
`(37).
`The use of 8-substituted xanthines, particularly the
`8-substituted theophyllines, as salt-forming agents was
`first reported in the preparation of a series of antihistamine
`salts (38-41). Synthesis ofthese xanthine salts was an at-
`tempt to find a drug to counteract the drowsiness caused
`by the antihistamines with the stimulant properties of the
`xanthines. When an electronegative group is introduced
`into the xanthine molecule at the 8-position, the elec-
`tron-drawing capacity of the substituent results in the
`creation of an acidic hydrogen at position Z. Thus, these
`
`4 / Journal of Pharmaceutical Sciences
`
`Sal1
`
`Acetylaminoa
`N-Acetyl-L-a
`N-Acetylcyst
`Adamantoic a
`Adipic acid
`N-Alkylsulfar
`
`Anthraquinor
`Arabogalactar
`Arginine
`
`Aspartate
`Betaine
`Bis(2-carboxy
`Carni{ine
`4-Chloro-m-tr
`Decanoate
`Diacetyl sulfa
`Dibenzylethyl
`Diethylamine
`Diguaiacyl ph
`Dioctyl sulfosr
`Embonic (pan
`
`Fructose 1,6-d
`
`,
`
`can undergo ra11 Table III-
`moderately strong acidic compounds
`formation with various organic bases.
`The 8-halotheophyllines were the first group of xan-
`thines studied as potential salt-forming agents. Since the
`report on the preparation of the 8-chlorotheophylline salt
`of diphenhydramine (42), synthesis of the 8-halotheo-
`phyllinates of a number of organic bases has been at-
`tempted. The 8-chlorotheophylline salts of quinine,
`ephedrine, and strychnine were prepared and character-
`ized (43). These salts were less water soluble than the
`corresponding free alkaloidal bases. In a similar report, the
`8-chlorotheophyllinates of three synthetic narcotics,
`meperidine, levorphanol, and metopon, were prepared
`(44).
`_ Pharmacological and clinical studies involving the g-
`bromotheophylline pyrilamine salt revealed the unusual
`diuretic properties associated with theE-halotheophylline
`portion of the compound (45, 46). This finding initiated
`an investigation into the preparation of a soluble 8-bro-
`motheophylline salt of high diuretic activity. With readily
`available amines, over 30 salts.were synthesized and
`screened for diuretic activity (4?). When tested against
`theophylline salts of the same amines, the 8-bromotheo-
`phyllinates showed greater activity in every case.
`With the successful formation of S-halotheophyllinates
`of organic bases, Morozowich and Bope (48) proposed that,
`if the halogen moiety was replaced with a more electro-
`negative substituent such as a nitro group, a more acidic
`compound would be formed. Presumably, more stable salts
`would result and precipitation of the free xanthine deriv-
`ative in the stomach would be less likely to occur. On this
`premise, they successfully prepared pharmacologically
`effective 8-nitrotheophyllinates of several pharmaceuti-
`cally useful bases.
`Duesel et al. (Lg), in their study of choline theophylli-
`nate, prepared the 8-chloro-,8-bromo-, and 8-nitrotheo-
`phylline salts of choline. Oral toxicity studies in mice
`showed that the LD56 of the 8-nitrotheophyllinate was
`much greater than that of either 8-halotheophylline. In
`fact, it remained nonlethal at doses as high as 5 g.
`Polygalacturonic acid, a derivative of pectin, has been
`used to prepare quinidine salts exhibiting reduced toxicity
`(49, 50). The compound possesses special demulceni
`properties and inhibits mucosal irritation. The rationale
`for use of this agent is to reduce the ionic shock to the GI
`mucosa resulting from the flood of irritating ions liberated
`by rapid dissociation of the conventional inorganic quin-
`idine salts. Studies have shown that it is foui timeJ less
`toxic orally than the sulfate. This difference was attributed
`to the slower release of quinidine from the polygalactu-
`ronate.
`Other compounds reported to be potentially useful as
`pharmaceutical salt forms are listed in Table III.
`
`Glucose 1-pho
`6-phosphpri
`t,-Glutamine
`Hydroxynaph
`2-(4-lmidazoll
`Isobutanolami
`Lauryl sulfate
`Lvsine
`
`Methanesulfor
`N-Methylgluc
`
`N-Methylpipe
`Morpholine
`2-Naphthalenr
`Octanoate
`Probenecid
`Tannic acid
`Theobromine I
`3,4,5-Trimeth<
`
`Tromethamint
`
`tion, the rel
`ministration
`In a reviel
`"different se
`logically the
`properties."
`panded upor
`nature of th
`salts of the s
`ciably, the ir
`The salt f<
`cochemical tr
`dissolution r
`These prope
`mulation chr
`pharmaceuti
`extensive prr
`properties ol
`suitable form
`concerning s
`tion studies l
`salt form on
`under invest:
`
`PHYSICOCHEMICAL STUDIES
`
`Biological activity of a drug molecule is influenced by
`two factors: its chemical structure and effect at a specific
`site and its ability to reach-and then be rernoved from-
`the site of action. Thus, a knowledge of the physicochem.
`ical properties of a compound that influence its absorption,
`distribution, metabolism, and excretion is essential for a
`complete understanding of the onset and duration of ac-
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1013 - Page 5
`
`

`
`llES oSrapu
`
`-uBx Jo dn(
`aql aculs's'
`?Ps auqldqt
`-oaqlolBr{-8
`-?€ uaoq sE
`'aururnb yc
`-JalcBrBqc I
`aql ueql al
`aql'lJodar J
`'scllocJeu
`pal€dard
`
`a,
`
`-8 aql 3uI^
`I€nsnun aq:
`ou{ldr{dooq
`palerlrur 3u
`-orq-8 aiqn
`dlpuar q1t1
`pu€ pozrsar
`lsurBSB pol
`-oaqlouroJq
`'asei
`saleuqdqd<
`'1uq1 pasodc
`-orlcela aro
`SrprcB alou
`sllBs olqEs (
`-^rJap auql
`sn{} uo'rnc
`.{1ecr3o1oce
`--rlna33ruJBr
`
`-r11dqdoaq1
`-oaqloJlru-[
`ACIUI UI SOI
`sBA\ Aleurlll
`u1 'autt1dqd
`'39r
`uaaq seq'ut
`dlrcrxol pact
`luorFurap
`alBuorl€r
`IC oql ol {c
`po?€raq{ su
`-urnb crueS;
`ssal salurl r
`palnqrr?}? sr
`-n1cep8f,1ot
`
`011
`
`se pyasn d1
`'n
`
`dq pacuang
`crlrcads e 1e
`-ruorJ paA(
`-ruaqcocrsdr
`'uorld.rosqe t
`B JoJ IErluos
`-cE Jo uorlBJ
`
`sluotv IBcltnoc?urrerld Jo srurod lI"S InJosn fIIBIluetod-III aIqW
`luaFy Sururrog-11e9
`palJ1po4 punoduro3
`
`uorl€rrJrpohl
`
`a)uaJaJau
`
`prce crlaceoutueldlacy
`aur8eredse-t-1,t1ecy-,y
`aur1s.{r1,{1aey-1y
`pIcE JroJueluupY
`prcu crdrpy
`seleure;1ns1fr11y-p
`
`prre cruoJlnslp-g'I -ououlnb€rqluv
`(ouIqBrB) e1eJPs uepeleSoqerY
`auturS.ry
`
`al€lrBdsV
`auIel0B
`sauu>1p (,{xo1d- g -uourorqc.{xoqrEr- Z )srfl
`aurlruJBJ
`prce JruoJlnsauenlol- Iu -oJolqc-l
`eJEouBJe0
`a1e3Ps 1.{lacetq
`au r u er paua1,{qla1,izu'aqiI
`auruulf,qlalC
`aleqdsoqd 1.{cetenBtq
`aleuncnsoSlns 1f,1cotq
`(ctourPd) cluoqug
`pr3€
`prce rr.roqdsoqdlp-g' I esolcnrd
`
`asoenl8'p1ce cr.roqdsoqd-1 asornlS
`pIJB ruot{dsoqd-9
`eururElnlc-.I
`aleoqlqdeudxorP.{g
`aururelf q1a(1{1oz€PIIuI-})-Z
`aurIu€iouBlnq0sl
`l.{rn€l
`a1€Jlns
`aursdl
`
`p_rc€ )ruoJlnsaueqlaI^l
`aururecniSl,{q1ey1-1y
`
`au rzeredr d 1dq1a141 -,y
`auqoqd;o1X
`prc€ cruoJlnsaualeqlqdelq-3
`el€ou81r0
`plJauaqord
`prJ€
`f,ruuPJ
`prJB JrlaJE aulluoJqoaqJ
`eluozuaq,{xoqlauruJ-9(t't
`
`aurIu€qlaruoJJ
`
`auqcIcdxog
`urcdruo.rqlr{.rg
`auqodcf,xoq
`sapruenBrql.{1iy
`aurzeradr4
`irqlcrduiy
`uIf,l{ruoJuIT
`urxaleqda3
`sprole{I€ snolre^
`sut.todsoPqda3
`urlircruadldzuaqoJlns- D
`urcdutolqilrg
`aur1c,{ce.r1etr,
`saurlldqdoaql(id{lEouIuIY) -t
`urruroJlaIAI
`aueqddxodor4
`1outue1da11
`euIIrrBrt{J
`uqltctdtuY
`surrodsoleqda3
`auqrdce.rle;,
`aurruecurn
`u r.lr{rueuey
`au r loqd.rour;.{qrau- g- 1.{uaq4-3
`aur1c.{cer1a;
`urcdurorqld.rg
`autlcr{ee.r1a.1
`urcduorqldrg
`urc,{urorq$.rg
`urntuaqdag
`utPue13e1so.t4
`euqlf,qdoeql
`eurIueculA
`uqlcruadldzuaqoJlnS-D
`surrodsoPqda3
`(I IVd-Z) aurxoPrlerd
`uqlcruedldzueqoJlns-P
`sur.rodsoPqde3
`auozelnqlduaq4
`surrodsoleqda3
`auaqddxodo.t4
`lourureldag
`uqlctdurerrt4
`saulIu€ snoIJ€A
`auaqddxodor4
`auIlc.{J€r?aJ
`lourui:1hag
`utrtdsY
`(^'ad urpuBlSelsord) ?sordoul(
`
`flllrqnlos
`f lqrqels'dl!^I?re'dlqtqnlog
`eruoruneud ur InJasn lJaJJa paulquroC
`uo1lce PaEuolo't6
`sarlradord ctldaloueEro'.{1rerxo1'dlll}qetS
`(Pro) uotldrosqY
`dlqtqnlog
`uorldrosqe'r(llllq€lS
`uotlce PaEuolo.r4
`.{lrcrxo;
`dltlxol'fycrdocsorS.{q',{llIIqBlS
`dlqtqnlog
`uotldrosqe JrrlsEC
`1ca;ga cr1ce1.{qdo;d pa8uoiord'd1nt1cy
`.{ltcrxo;
`satpado.rd rrldaioueBr6
`uorlce PaEuolo.r4
`flIcIdotsorS^t{'d?111q€1S
`uorlce PaSuolo't4
`uorlca[u1 uo uted PatnPoU
`d?rAtlry
`sailradord crldaloueFr6
`.{lterxoa
`dltctxo;
`d1111qn1og
`fltltqnlog
`dltltqnlog
`dltltqnlog
`.{11irqe1s'd1r,rr1ce'dlqtqnlog
`dlrctxo;
`uorlce PaFuolor4
`drlItq€ts
`satlrado.rd crldaloueS;g
`,{tIf, rdocsor8dq'f111tqe1s'dll)lIoJ
`
`.{lqrqnpg
`,{1rcrdocsor8.{q'd1qiqe1s'.{lrctxo;
`uorlra[u1 fio ured Pe]nPaU
`uoIl)E Jo Jasuo Jals€J
`'f,1tctxo;
`uotlca[u1 uo uted PeJnPaU
`satlrado.ril cr1da1oue3.rI
`uotlle PaSuoio.t4
`satlraclo.td rr1da1ouri8.rI
`uorlce PaBuolor4
`.{1trt1cy
`sarlradord cr1da1oue3.rg
`uorlee PaEuolor4
`(l€ro) uol?drosqV
`alels IBTISfI{d
`
`IS
`Z9
`cc
`v9
`c9
`99
`L9
`8q
`09'6S
`I9
`70
`89
`l9
`99
`o0
`L9
`89
`69
`IL,OL
`ZL
`
`,L
`9L
`9L
`LL
`
`LL
`
`Z9
`8L
`6L
`08
`I8
`Z9
`TO
`78
`Zg
`ZL
`88
`ZL
`t8
`89
`s8
`t8'98
`88
`68
`89
`06
`t-h
`
`-p€ Jo

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket